<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Patrick Hsu</title>
</head>
<body>
    <h1>Patrick Hsu</h1>

    <ul>
        <li>I'm a scientist, founder, and investor. I work with ambitious people to improve the human experience in our lifetimes.</li>
        <li>I was born in Taipei and raised on the west coasts of Canada and the United States. I completed my <a href="#">master's and PhD</a> at Harvard University and was an undergraduate at the University of California, Berkeley.</li>
        <li>I co-founded and help to lead the <a href="#">Arc Institute</a>, <a href="#">teach at UC Berkeley</a> (where I am an Assistant Professor of Bioengineering and Deb Faculty Fellow in the College of Engineering), and helped to <a href="#">start Fast Grants</a>.</li>
        <li>Before I ever touched a pipette, I studied Middle English textual criticism and computer science, and was homeschooled until college.</li>
    </ul>

    <h2>Science</h2>
    <ul>
        <li>I am a researcher working at the interface of biology, technology development, and machine learning.</li>
        <li>Learn more about our lab on our <a href="#">Arc</a> and <a href="#">Berkeley</a> pages. Here's a longer list of my <a href="#">publications</a>, <a href="#">patents</a>, and <a href="#">asteroid</a>.</li>
        <li>Some of our contributions or inventions include the discovery of the first <a href="#">programmable recombinases</a>, the <a href="#">Evo AI foundation model</a> trained on genomes, the most widely used <a href="#">tools</a> for <a href="#">CRISPR-based RNA targeting</a>, and CRISPR-Cas9 <a href="#">genome editing</a> in <a href="#">human cells</a>.</li>
        <li>I have co-founded multiple biotechnology and therapeutics companies, such as <a href="#">Stylus Medicine</a> and <a href="#">Circle Labs</a>, and was on the initial team at the <a href="#">first Cas9 therapeutics company</a> from a single conference room through IPO.</li>
        <li>Learn more via <a href="#">New Scientist</a>, <a href="#">Financial Times</a>, and <a href="#">Endpoints</a> on our bridge RNA discovery, <a href="#">STAT News</a> on our bio x AI research, an <a href="#">a16z podcast</a>, and <a href="#">New York Times</a> and 60 Minutes pieces on our diagnostics work.</li>
    </ul>

    <h2>Investing</h2>
    <ul>
        <li>I invest in and advise startups, including <a href="#">The Bot Company</a>, <a href="#">Varda Space</a>, <a href="#">Arbor Biotechnologies</a>, <a href="#">Vial Health</a>, <a href="#">Veda Bio</a>, <a href="#">Factory.ai</a>, <a href="#">Atomic.ai</a>, <a href="#">Medra.ai</a>, <a href="#">Sphinx.bio</a>, <a href="#">Teiko.bio</a>, <a href="#">Cradle.bio</a>, <a href="#">Nucleus Genomics</a>, <a href="#">Stipple Bio</a>, <a href="#">Dover</a>, <a href="#">Rewrite Therapeutics</a> (acquired, Intellia), <a href="#">Replace Therapeutics</a> (acquired), <a href="#">Serotiny</a> (acquired, J&J), and many more.</li>
        <li>I also invest with <a href="#">Nat Friedman and Daniel Gross</a> as a Venture Partner (investing <a href="#">$1M-$100M</a> at a time, e.g. co-leading the seed round in <a href="#">Evolution.io</a>).</li>
    </ul>
</body>
</html>
